We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.

The offering is entirely comprised of shares offered by Metsera, which could signal that existing investors are not participating in the IPO, potentially raising concerns about their confidence in ...

A Quick Take On Metsera, Inc. Metsera, Inc. (NASDAQ:MTSR) has filed to raise $275 million in an IPO of its common stock, according to SEC S-1/A registration information. The firm is a clinical ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...